Trabectedin Confers Long-Term Efficacy in Soft Tissue Sarcoma
A large prospective postcommercialization study in patients with advanced STS in Europe confirmed the long-term anticancer activity of trabectedin (Yondelis) in different subtypes of sarcoma.